Literature DB >> 23534856

Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A.

S L Sood1, A Cuker, C Wang, A D Metjian, E Y Chiang, J M Soucie, B A Konkle.   

Abstract

Type 3 von Willebrand's disease (VWD) is a rare bleeding diathesis with complete or near complete deficiency of von Willebrand factor (VWF) and low factor VIII (FVIII) levels. In contrast, only FVIII is decreased in haemophilia A (HA). Both disorders are complicated by arthropathy. The purpose of this study was to further clarify the roles of FVIII and VWF: Antigen (VWF:Ag) in joint range of motion (ROM) loss over time. We compared joint ROM loss and other bleeding manifestations in 100 Type 3 VWD subjects (FVIII<5%) and 1814 moderate HA subjects (FVIII 1-5%) within the U.S. Universal Data Collection (UDC) database. High rates of bleeding were reported at baseline. During follow-up, moderate HA patients reported a joint (46% vs. 34%, P < 0.0001) or muscle bleed (27% vs. 16%, P < 0.0001) in a higher proportion of visits than VWD patients. Other bleeds, including mucosal, were reported in a greater proportion of visits among patients with Type 3 VWD than among those with HA (49% vs. 32%, P < 0.0001). Multivariate analysis revealed no difference in joint ROM loss over time in the Type 3 VWD vs. moderate HA populations. A higher FVIII level was protective in both VWD and HA (P < 0.001). Our findings support the hypothesis of primacy of the FVIII level in determining risk of joint haemorrhage, and may help target therapy in Type 3 VWD and moderate HA to prevent joint disability.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23534856      PMCID: PMC4545639          DOI: 10.1111/hae.12119

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  25 in total

1.  Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia.

Authors:  K Fischer; J G van der Bom; E P Mauser-Bunschoten; G Roosendaal; F J Beek; P de Kleijn; D E Grobbee; H M van den Berg
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Range of motion measurements: reference values and a database for comparison studies.

Authors:  J M Soucie; C Wang; A Forsyth; S Funk; M Denny; K E Roach; D Boone
Journal:  Haemophilia       Date:  2010-11-11       Impact factor: 4.287

3.  Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).

Authors:  T C Abshire; A B Federici; M T Alvárez; J Bowen; M D Carcao; J Cox Gill; N S Key; P A Kouides; K Kurnik; A E Lail; F W G Leebeek; M Makris; P M Mannucci; R Winikoff; E Berntorp
Journal:  Haemophilia       Date:  2012-07-23       Impact factor: 4.287

4.  Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism.

Authors:  René J Berckmans; Rienk Nieuwland; Paul Peter Tak; Anita N Böing; Fred P H T M Romijn; Maarten C Kraan; Ferdinand C Breedveld; C Erik Hack; Augueste Sturk
Journal:  Arthritis Rheum       Date:  2002-11

5.  Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study.

Authors:  Susan Halimeh; Anne Krümpel; Hannelore Rott; Nadja Bogdanova; Ulrich Budde; Daniela Manner; Britta Faeser; Rolf Mesters; Ulrike Nowak-Göttl
Journal:  Thromb Haemost       Date:  2011-02-08       Impact factor: 5.249

Review 6.  Prophylaxis in von Willebrand disease.

Authors:  E Berntorp
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

7.  Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.

Authors:  M Lak; F Peyvandi; P M Mannucci
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 8.  Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 9.  Prophylaxis of bleeding episodes in patients with von Willebrand's disease.

Authors:  Augusto B Federici
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

10.  Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.

Authors:  J Michael Soucie; Christy Cianfrini; Robert L Janco; Roshni Kulkarni; Julie Hambleton; Bruce Evatt; Angela Forsyth; Sue Geraghty; Keith Hoots; Tom Abshire; Randall Curtis; Ann Forsberg; Heather Huszti; Margaret Wagner; Gilbert C White
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

View more
  1 in total

1.  [Total ankle replacement in patients with bleeding disorders].

Authors:  A Barg; K Barg; M Wiewiorski; S W Schneider; M D Wimmer; D C Wirtz; V Valderrabano; G Pagenstert
Journal:  Orthopade       Date:  2015-08       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.